These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12028045)

  • 1. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
    Gerotziafas GT; Zervas K; Arzoglou P; Karavaggeli E; Parashou S; Van Dreden P; Christakis J; Samama MM
    Br J Haematol; 2002 Jun; 117(3):705-8. PubMed ID: 12028045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
    Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
    Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
    Tranholm M; Rojkjaer R; Pyke C; Kristensen AT; Klitgaard B; Lollike K; Blajchman MA
    Thromb Res; 2003 Feb; 109(4):217-23. PubMed ID: 12757777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
    Gerotziafas GT; Zervas C; Gavrielidis G; Tokmaktsis A; Hatjiharissi E; Papaioannou M; Lazaridou A; Constantinou N; Samama MM; Christakis J
    Am J Hematol; 2002 Mar; 69(3):219-22. PubMed ID: 11891811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
    Martinowitz U; Holcomb JB; Pusateri AE; Stein M; Onaca N; Freidman M; Macaitis JM; Castel D; Hedner U; Hess JR
    J Trauma; 2001 Apr; 50(4):721-9. PubMed ID: 11303171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
    Allen GA; Hoffman M; Roberts HR; Monroe DM
    Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.
    Bowles KM; Callaghan CJ; Taylor AL; Harris RJ; Pettigrew GJ; Baglin TP; Park GR
    Br J Anaesth; 2006 Oct; 97(4):476-81. PubMed ID: 16914465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count.
    Lisman T; Adelmeijer J; Cauwenberghs S; Van Pampus EC; Heemskerk JW; De Groot PG
    J Thromb Haemost; 2005 Apr; 3(4):742-51. PubMed ID: 15842358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
    Goodnough LT
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):25-9. PubMed ID: 14872417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
    Laurian Y
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():37-40. PubMed ID: 12214146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
    Martinowitz U; Kenet G; Segal E; Luboshitz J; Lubetsky A; Ingerslev J; Lynn M
    J Trauma; 2001 Sep; 51(3):431-8; discussion 438-9. PubMed ID: 11535886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
    Lauritzen B; Tranholm M; Ezban M
    J Thromb Haemost; 2009 Apr; 7(4):651-7. PubMed ID: 19175492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
    Kessler C
    Intensive Care Med; 2002 Oct; 28 Suppl 2():S228-34. PubMed ID: 12404091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
    Larsen OH; Clausen N; Persson E; Ezban M; Ingerslev J; Sørensen B
    Br J Haematol; 2009 Jan; 144(1):99-106. PubMed ID: 19016728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
    Martinowitz U; Michaelson M;
    J Thromb Haemost; 2005 Apr; 3(4):640-8. PubMed ID: 15842347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U
    Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.